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P
erhaps one of the most devastating diabetes
complications is diabetic embryopathy, in which
the offspring of a mother with diabetes predating
pregnancy develops congenital malformations.
These malformations can affect multiple organ systems,
including the brain and spinal cord, the heart and major
vessel, the kidneys, the gut, and skeletal structures (1,2)
and result in pre- or postnatal mortality or disability. As
malformations are induced during the earliest stages of
organogenesis, coinciding with the ﬁrst recognition of
pregnancy (3), it is important to institute rigorous glyce-
mic control before the onset of pregnancy. Nevertheless,
recent studies (4,5) have shown that even in planned
pregnancies with optimal prepregnancy care, the inci-
dence of malformations in diabetic pregnancies is still at
least twice that in nondiabetic pregnancies. As malforma-
tions occur in the offspring of women with either type 1 or
type 2 diabetes (or offspring of women who are obese
at the beginning of pregnancy and may have undiagnosed
type 2 diabetes) (2,6–8), and recent evidence indicates
that the incidence of diabetes, particularly type 2 diabetes,
predating pregnancy is rapidly increasing (9), the burden
of this diabetes complication is likely to increase in
coming years unless efforts to prevent diabetic embryop-
athy are improved. However, unlike other diabetes com-
plications, in which the development of pharmacologic
interventions offer the hope of treatment or prevention,
prevention of diabetic embryopathy is unlikely to beneﬁt
from pharmacologic intervention, because of the risk that
drugs that might interfere with diabetic teratogenic path-
ways might be teratogenic themselves. For example, we
have shown that maternal hyperglycemia before organo-
genesis stimulates production of diacyl glycerol and activ-
ity of protein kinase C (PKC) in mouse embryos during
formation of the neural tube (10). And yet, while recent
ﬁndings indicate that use of PKC inhibitors may be efﬁca-
cious for treating diabetic retinopathy (11,12), it is not
feasible to use PKC inhibitors during diabetic pregnancy
because they would disrupt angiogenesis, which is neces-
sary for successful implantation, placentation, and orga-
nogenesis. Thus, because development of pharmacologic
intervention in diabetic pregnancy proves especially chal-
lenging, it is all the more important to continue to inves-
tigate the mechanisms by which diabetic embryopathy
occurs in order to devise feasible approaches to reduce its
incidence.
Nevertheless, less appears to be known on a cellular and
molecular level how diabetic embryopathy occurs com-
pared with macro- and microvascular complications. The
scientiﬁc challenge to understanding the pathogenesis of
diabetic embryopathy can be partly attributed to the
diversity of tissues that can be affected and to the dynamic
changing state of differentiation of vulnerable organs
during the embryopathy-susceptible period. That is, the
cellular damage that occurs in differentiated tissues lead-
ing to macro- and microvascular disease may also occur in
differentiating embryo tissues, but, in addition, malforma-
tion may result because signaling caused by excess glu-
cose metabolism interferes with tissue morphogenesis.
The study by Wentzel, Ga ¨reskog, and Eriksson (13)
illustrates some of the difﬁculties inherent in experimen-
tally investigating diabetic embryopathy and why research
in this ﬁeld often proceeds in only incremental steps. In
this study, the authors hypothesized that several candidate
genes (such as those involved in antioxidative pathways,
apoptosis, or morphogenesis) might be altered as a result
of maternal diabetes in a rat model and examined expres-
sion of these candidate genes in embryos of nondiabetic
rats, as well as in normal and malformed embryos of
diabetic rats. They also examined markers of apoptosis in
the ﬁrst visceral arch and the heart, structures that are
prone to malformation in the diabetic model. This is not
the ﬁrst study by these authors, or others, on these
candidate genes or markers of apoptosis, but this study
does offer some new insights. In this study, differences in
gene expression and markers of apoptosis were observed
between embryos of diabetic and nondiabetic rats, partic-
ularly in malformed embryos. However, because the ob-
servations were made after structures were formed, it
cannot be determined whether the genes whose expres-
sion were affected were at all involved in causing the
malformations. As the authors state, they can only claim
an association with diabetic exposure or malformation. To
determine whether genes whose expression differed in
embryos from diabetic pregnancies could be involved in
causing malformations, investigators would need to con-
ﬁrm that expression is altered in embryos before malfor-
mations are apparent. Although, because malformations
are not yet apparent, it cannot be determined which
embryo(s) will become defective. If altered gene expres-
sion is responsible for malformations, it must be detect-
able (either in the aggregate of individually assayed
embryos, or pooled exposed embryos) before malforma-
tions are apparent. Then, to show that altered gene expres-
sion contributes to malformations, it is necessary to
manipulate gene expression to demonstrate that causing
the same change in gene expression (increase or decrease)
that is affected by diabetes replicates the effects of diabe-
tes on embryos and that blocking the change in gene
expression prevents the effects of diabetes on embryos.
While embryo gene expression can be manipulated in
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nologies), this is not currently possible in the rat. Thus,
while it should be possible to investigate whether the gene
expression changes noted in embryos after malformations
occur can also be detected before manifestation of mal-
formations, it is not currently possible to manipulate
expression of these genes in rat embryos; thus, the inves-
tigators can only conclude that there is an association with
diabetic teratogenesis, as Wentzel, Ga ¨reskog, and Eriks-
son have carefully done.
Another challenge that confronts this kind of research is
the relatively small differences in expression of candidate
genes that can lead to disparate ﬁndings when the same
genes are studied in different labs or even in the same lab
using different methods. Wentzel, Ga ¨reskog, and Eriksson
(13) discuss how they and others have previously investi-
gated expression of some of the same candidate genes
studied in this report and propose why some of the results
are at variance with previously published results. Never-
theless, because metabolic and signaling networks operate
in concert, small changes in gene expression or enzymatic
activity may be difﬁcult to detect consistently, but the
biological consequences may be ampliﬁed if several par-
ticipants in a signal transduction cascade are similarly
affected. Given the difﬁculty in determining whether or not
expression of candidate genes or activity of candidate
enzymes is consistently altered in different experimental
settings, it seems that the efforts of research into the
mechanisms responsible for diabetic embryopathy should
focus on asking the questions: 1) Are these changes in
gene expression or enzymatic activity functionally signiﬁ-
cant in causing malformations in diabetic pregnancy? and
2) If these genes/enzymes are not responsible for diabetic
embryopathy, how do they occur?
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